Fig 1.
miR-195 expression and impact on diagnosis and outcome of patients with PCa.
A) Data in the re-analysed MSKCC prostate cancer database showed that miR-195 is expressed poorly metastatic PCa (metastatic PCa vs. localised PCa: 9.92 ± 0.56 vs. 11.27 ± 0.07, P < 0.0001). B) ROC analysis using expression levels of miR-195 in metastatic PCa and localised PCa (AUC = 0.705, P = 0.017). C) Kaplan–Meier curves of RFS of patients with PCa stratified by the tissues of miR-195 levels. Patients with low miR-195 levels exhibited shorter RFS than those with high levels (P < 0.05) *P < 0.05.
Fig 2.
miR-195 inhibited EMT in PCa cells.
A) Forced expression of miR-195 inhibited migration in PCa cell lines. B) Forced expression of miR-195 inhibited invasion in PCa cell lines. C) Common EMT markers expression after transfecting miR-195. *P<0.05. Original magnification ×200.
Fig 3.
FGF2 was a direct target of miR-195
A) Sequence alignment of human miR-195 with 3’ UTR of FGF2 predicted by DIANA LAB. B) Dual-luciferase assay results for PC-3 cells showed that miR-195 upregulation decreased luciferase activity. C) FGF2 protein expression in PCa cell lines was determined through Western blot analysis at 72 h post-transfection. GAPDH was used as a control. *P<0.05.
Table 1.
Predicted binding sites of miR-195 for FGF2.
Fig 4.
FGF2 knockdown resulted similar effects in PCa cells with overexpress miR-195
A and B) Low expression of FGF2 inhibited migration and invasion in PCa cell lines. C) FGF2 and common EMT markers expression after siFGF2 was transfected. *P < 0.05.
Fig 5.
miR-195 inhibited EMT in an FGF2-dependent manner.
PCa cell lines were treated with recombinant human FGF2 protein after transfection with miR-195 was performed. A) The number of migrated cells increased after treatment. B) The number of invaded cells increased after treatment. C) Common EMT markers expression after 48 h of treatment.
Fig 6.
FGF2 expression impact outcome of patients with PCa.
Kaplan–Meier curves of RFS of patients with PCa stratified by the tissues of FGF2 levels. In Lapointe’s study patients with high FGF2 levels exhibited shorter RFS than those with high levels (P < 0.05).